Hologic Q4 2021 Earnings Report
Key Takeaways
Hologic announced strong Q4 2021 results, with revenue exceeding expectations. The company's diversified business, particularly in women's health, drove growth despite a decline in COVID-19 assay sales compared to the prior year period. Hologic is guiding for continued growth in fiscal year 2022, driven by core women’s health businesses and contributions from COVID-19 testing.
Revenue reached $1.317 billion, a decrease of 2.3% year-over-year, driven by lower COVID-19 assay sales.
Global revenue from Breast Health and GYN Surgical divisions grew 15.6% and 21.8%, respectively.
Diagnostics revenue decreased by 10.9%, but excluding COVID-19 assays, grew by 5.1%.
The company acquired Bolder Surgical for approximately $160 million.
Hologic
Hologic
Hologic Revenue by Segment
Hologic Revenue by Geographic Location
Forward Guidance
Hologic expects strong financial results in fiscal 2022, with solid growth in core women’s health businesses and a meaningful contribution from COVID-19 testing.
Positive Outlook
- Expects strong financial results in fiscal 2022.
- Solid growth in core women’s health businesses.
- Meaningful contribution from COVID-19 testing.
- Acessa will be included in organic revenue for the full year.
- Biotheranostics and Diagenode will become part of organic revenue in the fiscal third quarter.
Challenges Ahead
- Revenue $3,750 - $4,000 (33.4%) to (29.0%)
- GAAP EPS $2.50 - $2.80 (65.3%) to (61.2%)
- Non-GAAP EPS $3.55 - $3.85 (57.8%) to (54.2%)
- Q1 2022 Revenue $1,100 - $1,150 (31.7%) to (28.6%)
- Q1 2022 GAAP EPS $0.88 - $0.98 (64.8%) to (60.8%)
Revenue & Expenses
Visualization of income flow from segment revenue to net income